Claims for Patent: 10,426,779

Summary for Patent: 10,426,779

Title:	Induction of tumor hypoxia for cancer therapy
Abstract:	Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region. The activated hypoxia-activated bioreductive agents kill tumor cells in the hypoxic region by to catalyzing DNA stand breakage within the tumor cells. Because the activity is localized, side effects that typically occur as a result of systemic administration of bioreductive agents are reduced.
Inventor(s):	Lee; Ruey-min (Short Hills, NJ), Lin; Peck-sun (Richmond, VA)
Assignee:	VIRGINIA COMMONWEALTH UNIVERSITY (Richmond, VA)
Application Number:	15/480,250
Patent Claims:	1. A method of treating a solid tumor in a subject, comprising administering to the subject a hypoxia-activated bioreductive agent and one or more hypoxia-inducing agents, wherein the one or more hypoxia-inducing agents comprise combretastatin or a combretastatin derivative, wherein the hypoxia-activated bioreductive agent is tirapazamine, wherein the hypoxia-activated bioreductive agent is administered before or concurrently with the one or more hypoxia-inducing agents, and wherein the administration is in an amount effective in inducing necrosis of the solid tumor after 3 days of the administration. 2. The method of claim 1, wherein the hypoxia-activated bioreductive agent is administered before the one or more hypoxia-inducing agents are administered. 3. The method of claim 1, wherein the hypoxia-activated bioreductive agent is administered concurrently with the one or more hypoxia-inducing agents. 4. The method of claim 1, wherein the one more hypoxia-inducing agents further comprise an anti-angiogenic agent. 5. The method of claim 4, wherein the anti-angiogenic agent is selected from the group consisting of: bevacizumab, sorafenib, sunitinib, aflibercept, IMC-1C11, vatalanib (PTK-87), N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethy-1)amino]-- 3-pyridinecarboxamide (AMG 706), 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]- - -isothiazole-4-carboxylic acid amide (CP-547,632), pazopanib (GW-786034), N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), and cediranib (AXD-2171). 6. The method of claim 1, wherein the administration of the hypoxia-activated bioreductive agent and the one or more hypoxia-inducing agents synergistically induces necrosis in said solid tumor by at least about 5 fold as compared to administering the hypoxia-activated bioreductive agent and/or the one or more hypoxia-inducing agents alone. 7. The method of claim 1, wherein about 1 mg to about 300 mg of the hypoxia-activated bioreductive agent is administered to the subject. 8. The method of claim 1, wherein about 5 mg to about 200 mg of the hypoxia-activated bioreductive agent is administered to the subject. 9. The method of claim 1, wherein the solid tumor is a liver cancer. 10. The method of claim 1, wherein the one or more hypoxia-inducing agents comprise the combretastatin. 11. The method of claim 1, wherein the one or more hypoxia-inducing agents comprise the combretastatin derivative.

Details for Patent 10,426,779

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-10-23
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	11/18/2011		2039-10-23
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	08/16/2018		2039-10-23